In 754 adolescents in Brazil randomised 2:1 to the live-attenuated chikungunya vaccine VLA1553 or placebo, 98.8% of seronegative participants had seroprotective antibodies at 28 days and 98.3% at 12 months; related adverse events 70% vs 48%.
RCTn = 754
Buerger et al. Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil